7. October 2009 06:50
Isolagen, Inc. has reorganized and emerged from bankruptcy as Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on developing regenerative fibroblast cells for aesthetic, medical and scientific applications. The Company has named a new Board of Directors. The Food and Drug Administration (FDA) is currently reviewing the biologics license application (BLA) for Fibrocell Science's lead therapy, azfibrocel-T (formerly Isolagen Therapy), in development to treat nasolabial fold wrinkles. Azfibrocel-T is the sole topic for discussion at the Cellular, Tissue and Gene Therapies Advisory Committee Meeting on October 9, 2009 in Bethesda, MD.
SOURCE Fibrocell Science, Inc.
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe